Carfilzomib
Sold as Kyprolis, Karpilred, Carfilzomib cipla, Xomicib
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 4
- Registrations
- 6
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Amgen south africa (pty)ltd | Kyprolis | Not stated | 510679 | S4 | None |
| Dr Reddyæs Laboratories (Pty) LtdCertificate held by Dr. Reddy’s Laboratories (Pty) Ltd | Karpilred | 60 mg | 590228 | S4 | PIPIL |
| Cipla Medpro (Pty) Ltd | Carfilzomib cipla | 60 mg | 590360 | S4 | PIPIL |
| Lebasi Pharmaceuticals (Pty) Ltd | Xomicib | 10 mg/10 ml, 30 mg/30 ml, 60 mg/50 ml | 590431, 590432, 590433 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Kyprolis EACH 50 ml VIAL CONTAINS :CARFILZOMIB 60,0 mg | Not listed | 51067951/26/0679 | Registered | S4 | None |
| Karpilred EACH 50,0 ml SOLUTION CONTAINS: CARFILZOMIB 60,0 mg | 60 mgPowder for solution for infusion | 59022859/26/0228Approved 28 July 2026 | Registered | S4 | PIPIL |
| Carfilzomib cipla EACH VIAL CONTAINS: CARFILZOMIB 60,0 mg | 60 mgPowder for solution for infusion | 59036059/26/0360Approved 10 March 2026 | Registered | S4 | PIPIL |
| Xomicib 10 mg/10 ML EACH 10,0 ml VIAL CONTAINS: CARFILZOMIB 10,0 mg | 10 mg/10 ml | 59043159/26/0431 | Registered | S4 | None |
| Xomicib 30 mg/30 ML EACH 30,0 ml VIAL CONTAINS: CARFILZOMIB 30,0 mg | 30 mg/30 ml | 59043259/26/0432 | Registered | S4 | None |
| Xomicib 60 mg/50 ML EACH 50,0 ml VIAL CONTAINS: CARFILZOMIB 60,0 mg | 60 mg/50 ml | 59043359/26/0433 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Carfilzomib
S4: Carfilzomib
Consolidated Schedules 06 July 2026, line 5671
Pharmacological class: Cytostatic agents (class 26)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Karpilred, Dr Reddyæs Laboratories (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.